> top > docs > PubMed:32450149 > annotations

PubMed:32450149 JSONTXT

Annnotations TAB JSON ListView MergeView

sonoma2

Id Subject Object Predicate Lexical cue
T0 0-7 POSREG denotes Agonist
T1 11-15 GENE denotes RORA
T2 11-15 GENE denotes RORA
T3 16-26 NEGREG denotes Attenuates
T4 27-51 DISEASE denotes Nonalcoholic Fatty Liver
T5 52-63 CPA denotes Progression
T6 76-89 POSREG denotes Up-regulation
T7 102-105 GENE denotes 122
T8 126-137 REG denotes Development
T9 141-169 DISEASE denotes nonalcoholic steatohepatitis
T10 142-171 DISEASE denotes onalcoholic steatohepatitis (
T11 171-175 DISEASE denotes NASH
T12 180-190 REG denotes associated
T13 191-195 REG denotes with
T14 196-206 NEGREG denotes reductions
T15 218-229 GENE denotes microRNA122
T16 231-237 GENE denotes MIR122
T17 233-239 GENE denotes R122);
T18 244-273 GENE denotes RAR related orphan receptor A
T19 275-279 GENE denotes RORA
T20 277-281 GENE denotes RA)
T21 281-289 POSREG denotes promotes
T22 290-300 MPA denotes expression
T23 304-310 GENE denotes MIR122
T24 306-312 GENE denotes R122.
T25 312-322 POSREG denotes Increasing
T26 323-333 MPA denotes expression
T27 337-341 GENE denotes RORA
T28 339-343 GENE denotes RA i
T29 360-369 POSREG denotes increases
T30 370-380 MPA denotes expression
T31 384-390 GENE denotes MIR122
T32 386-392 GENE denotes R122 a
T33 395-402 NEGREG denotes reduces
T34 403-415 MPA denotes lipotoxicity
T35 405-417 DISEASE denotes potoxicity.
T36 437-444 REG denotes effects
T37 450-454 GENE denotes RORA
T38 452-456 GENE denotes RA a
T39 455-462 POSREG denotes agonist
T40 482-486 DISEASE denotes NASH
T41 540-548 POSREG denotes agonists
T42 552-556 GENE denotes RORA
T43 553-557 GENE denotes ORA
T44 574-581 REG denotes effects
T45 593-617 DISEASE denotes hepatocellular carcinoma
T46 594-618 DISEASE denotes epatocellular carcinoma
T47 630-634 GENE denotes uh7)
T48 654-657 REG denotes fed
T49 703-709 REG denotes induce
T50 710-715 DISEASE denotes fatty
T51 773-779 GENE denotes of a M
T52 778-784 GENE denotes MIR122
T53 785-795 NEGREG denotes antagonist
T54 797-810 MPA denotes antagomiR-122
T55 825-834 MPA denotes antagomiR
T56 931-935 GENE denotes the
T57 936-940 GENE denotes RORA
T58 949-956 MPA denotes RS-2982
T59 1066-1074 REG denotes analyzed
T60 1194-1197 REG denotes fed
T61 1249-1256 MPA denotes RS-2982
T62 1282-1290 REG denotes analyzed
T63 1331-1339 REG denotes analyzed
T64 1344-1350 MPA denotes levels
T65 1354-1371 MPA denotes aminotransferases
T66 1428-1432 DISEASE denotes NASH
T67 1518-1524 GENE denotes mice
T68 1529-1542 MPA denotes antagomiR-122
T69 1557-1564 NEGREG denotes reduced
T70 1565-1571 MPA denotes levels
T71 1575-1581 GENE denotes MIR122
T72 1645-1658 MPA denotes antagomiR-122
T73 1670-1679 POSREG denotes increased
T74 1680-1692 MPA denotes fat droplets
T75 1697-1723 MPA denotes total triglyceride content
T76 1737-1744 NEGREG denotes reduced
T77 1745-1756 MPA denotes β-oxidation
T78 1761-1779 MPA denotes energy expenditure
T79 1781-1790 REG denotes resulting
T80 1791-1793 REG denotes in
T81 1808-1812 POSREG denotes more
T82 1813-1824 CPA denotes weight gain
T83 1850-1854 GENE denotes ntro
T84 1880-1887 MPA denotes RS-2982
T85 1894-1901 POSREG denotes agonist
T86 1894-1900 GENE denotes agonis
T87 1905-1909 GENE denotes RORA
T88 1922-1926 GENE denotes to
T89 1926-1934 POSREG denotes increase
T90 1935-1945 MPA denotes expression
T91 1956-1973 MPA denotes promoter activity
T92 2023-2029 GENE denotes diet,
T93 2043-2050 MPA denotes RS-2982
T94 2051-2060 POSREG denotes increased
T95 2069-2075 MPA denotes levels
T96 2079-2096 MPA denotes MIR122 precursors
T97 2101-2108 NEGREG denotes reduced
T98 2117-2126 MPA denotes synthesis
T99 2130-2143 MPA denotes triglycerides
T100 2147-2155 NEGREG denotes reducing
T101 2156-2166 MPA denotes expression
T102 2170-2190 MPA denotes biosynthesis enzymes
T103 2182-2202 DISEASE denotes enzymes. In these m
T104 2207-2214 MPA denotes RS-2982
T105 2212-2226 DISEASE denotes 82 significant
T106 2229-2236 NEGREG denotes reduced
T107 2245-2257 MPA denotes lipotoxicity
T108 2259-2266 NEGREG denotes reduced
T109 2267-2281 CPA denotes liver fibrosis
T110 2283-2292 POSREG denotes increased
T111 2301-2311 MPA denotes resistance
T112 2317-2324 NEGREG denotes reduced
T113 2325-2336 CPA denotes body weight
T114 2404-2410 GENE denotes rdiova
T115 2429-2438 POSREG denotes increased
T116 2439-2445 MPA denotes levels
T117 2456-2462 GENE denotes MIR122
T118 2479-2485 MPA denotes levels
T119 2487-2493 GENE denotes efore
T120 2502-2511 POSREG denotes increased
T121 2512-2522 MPA denotes expression
T122 2533-2539 GENE denotes MIR122
T123 2544-2554 REG denotes associated
T124 2555-2559 REG denotes with
T125 2560-2569 POSREG denotes increased
T126 2570-2576 MPA denotes levels
T127 2572-2576 GENE denotes vels
T128 2587-2603 MPA denotes free fatty acids
T129 2608-2614 MPA denotes levels
T130 2618-2622 GENE denotes RORA
T131 2640-2650 REG denotes identified
T132 2642-2646 GENE denotes enti
T133 2664-2671 MPA denotes RS-2982
T134 2676-2682 GENE denotes n agon
T135 2678-2685 POSREG denotes agonist
T136 2689-2693 GENE denotes RORA
T137 2699-2708 POSREG denotes increases
T138 2709-2719 MPA denotes expression
T139 2723-2729 GENE denotes MIR122
T140 2792-2812 DISEASE denotes ic diet given inject
T141 2814-2828 DISEASE denotes ns of RS-2982
T142 2820-2827 MPA denotes RS-2982
T143 2832-2839 NEGREG denotes reduced
T144 2840-2860 CPA denotes hepatic lipotoxicity
T145 2862-2876 CPA denotes liver fibrosis
T146 2882-2893 CPA denotes body weight
T147 2897-2901 GENE denotes pare
T148 2932-2940 POSREG denotes Agonists
T149 2944-2948 GENE denotes RORA
T150 2958-2967 REG denotes developed
T151 2972-2981 REG denotes treatment
T152 2985-2989 DISEASE denotes NASH
R0 T0 T3 CauseOf Agonist,Attenuates
R76 T71 T70 ThemeOf MIR122,levels
R77 T71 T69 ThemeOf MIR122,reduced
R78 T72 T76 CauseOf antagomiR-122,reduced
R79 T72 T79 CauseOf antagomiR-122,resulting
R80 T72 T80 CauseOf antagomiR-122,in
R81 T72 T81 CauseOf antagomiR-122,more
R82 T74 T73 ThemeOf fat droplets,increased
R83 T74 T76 ThemeOf fat droplets,reduced
R84 T75 T73 ThemeOf total triglyceride content,increased
R85 T75 T76 ThemeOf total triglyceride content,reduced
R86 T78 T76 ThemeOf energy expenditure,reduced
R87 T79 T76 CauseOf resulting,reduced
R88 T80 T76 CauseOf in,reduced
R89 T76 T81 CauseOf reduced,more
R90 T77 T76 ThemeOf β-oxidation,reduced
R143 T126 T125 ThemeOf levels,increased
R144 T126 T123 ThemeOf levels,associated
R145 T126 T124 ThemeOf levels,with
R146 T128 T126 ThemeOf free fatty acids,levels
R147 T128 T124 ThemeOf free fatty acids,with
R148 T128 T125 ThemeOf free fatty acids,increased
R149 T129 T123 ThemeOf levels,associated
R150 T129 T124 ThemeOf levels,with
R151 T129 T125 ThemeOf levels,increased
R152 T130 T129 ThemeOf RORA,levels
R153 T130 T126 ThemeOf RORA,levels
R154 T133 T131 ThemeOf RS-2982,identified
R155 T135 T131 ThemeOf agonist,identified
R1 T4 T0 ThemeOf Nonalcoholic Fatty Liver,Agonist
R2 T5 T0 ThemeOf Progression,Agonist
R3 T0 T6 CauseOf Agonist,Up-regulation
R4 T1 T0 ThemeOf RORA,Agonist
R5 T5 T3 ThemeOf Progression,Attenuates
R6 T4 T3 ThemeOf Nonalcoholic Fatty Liver,Attenuates
R7 T4 T5 ThemeOf Nonalcoholic Fatty Liver,Progression
R8 T4 T6 ThemeOf Nonalcoholic Fatty Liver,Up-regulation
R9 T5 T6 ThemeOf Progression,Up-regulation
R10 T6 T3 CauseOf Up-regulation,Attenuates
R11 T7 T6 ThemeOf 122,Up-regulation
R12 T8 T12 ThemeOf Development,associated
R13 T9 T6 ThemeOf nonalcoholic steatohepatitis,Up-regulation
R14 T9 T8 ThemeOf nonalcoholic steatohepatitis,Development
R15 T9 T12 ThemeOf nonalcoholic steatohepatitis,associated
R16 T9 T13 ThemeOf nonalcoholic steatohepatitis,with
R17 T9 T14 ThemeOf nonalcoholic steatohepatitis,reductions
R18 T9 T21 ThemeOf nonalcoholic steatohepatitis,promotes
R19 T9 T22 ThemeOf nonalcoholic steatohepatitis,expression
R20 T11 T6 ThemeOf NASH,Up-regulation
R21 T11 T8 ThemeOf NASH,Development
R22 T11 T12 ThemeOf NASH,associated
R23 T11 T13 ThemeOf NASH,with
R24 T11 T14 ThemeOf NASH,reductions
R25 T11 T21 ThemeOf NASH,promotes
R26 T11 T22 ThemeOf NASH,expression
R27 T14 T21 CauseOf reductions,promotes
R28 T15 T13 ThemeOf microRNA122,with
R29 T15 T14 ThemeOf microRNA122,reductions
R30 T15 T22 ThemeOf microRNA122,expression
R31 T16 T13 ThemeOf MIR122,with
R32 T16 T14 ThemeOf MIR122,reductions
R33 T18 T14 ThemeOf RAR related orphan receptor A,reductions
R34 T18 T22 ThemeOf RAR related orphan receptor A,expression
R35 T22 T21 ThemeOf expression,promotes
R36 T23 T22 ThemeOf MIR122,expression
R37 T23 T21 ThemeOf MIR122,promotes
R38 T26 T25 ThemeOf expression,Increasing
R39 T25 T29 CauseOf Increasing,increases
R40 T25 T33 CauseOf Increasing,reduces
R41 T27 T26 ThemeOf RORA,expression
R42 T27 T25 ThemeOf RORA,Increasing
R43 T29 T33 CauseOf increases,reduces
R44 T30 T29 ThemeOf expression,increases
R45 T31 T30 ThemeOf MIR122,expression
R46 T30 T33 ThemeOf expression,reduces
R47 T31 T29 ThemeOf MIR122,increases
R48 T34 T33 ThemeOf lipotoxicity,reduces
R49 T37 T36 ThemeOf RORA,effects
R50 T36 T39 ThemeOf effects,agonist
R51 T37 T39 ThemeOf RORA,agonist
R52 T40 T39 ThemeOf NASH,agonist
R53 T40 T36 ThemeOf NASH,effects
R54 T44 T41 ThemeOf effects,agonists
R55 T45 T41 ThemeOf hepatocellular carcinoma,agonists
R56 T42 T41 ThemeOf RORA,agonists
R57 T42 T44 ThemeOf RORA,effects
R58 T45 T44 ThemeOf hepatocellular carcinoma,effects
R59 T45 T53 ThemeOf hepatocellular carcinoma,antagonist
R60 T50 T48 ThemeOf fatty,fed
R61 T50 T49 ThemeOf fatty,induce
R62 T52 T53 ThemeOf MIR122,antagonist
R63 T52 T54 ThemeOf MIR122,antagomiR-122
R64 T52 T55 ThemeOf MIR122,antagomiR
R65 T54 T53 ThemeOf antagomiR-122,antagonist
R66 T55 T53 ThemeOf antagomiR,antagonist
R67 T57 T53 ThemeOf RORA,antagonist
R68 T57 T58 ThemeOf RORA,RS-2982
R69 T64 T62 ThemeOf levels,analyzed
R70 T64 T63 ThemeOf levels,analyzed
R71 T65 T64 ThemeOf aminotransferases,levels
R72 T65 T62 ThemeOf aminotransferases,analyzed
R73 T65 T63 ThemeOf aminotransferases,analyzed
R74 T68 T73 CauseOf antagomiR-122,increased
R75 T70 T69 ThemeOf levels,reduced
R91 T77 T79 ThemeOf β-oxidation,resulting
R92 T81 T80 ThemeOf more,in
R93 T82 T79 ThemeOf weight gain,resulting
R94 T82 T80 ThemeOf weight gain,in
R95 T82 T81 ThemeOf weight gain,more
R96 T84 T85 ThemeOf RS-2982,agonist
R97 T84 T89 CauseOf RS-2982,increase
R98 T85 T89 CauseOf agonist,increase
R99 T87 T84 ThemeOf RORA,RS-2982
R100 T87 T85 ThemeOf RORA,agonist
R101 T91 T89 ThemeOf promoter activity,increase
R102 T90 T89 ThemeOf expression,increase
R103 T90 T91 ThemeOf expression,promoter activity
R104 T93 T97 CauseOf RS-2982,reduced
R105 T95 T94 ThemeOf levels,increased
R106 T94 T97 CauseOf increased,reduced
R107 T94 T100 CauseOf increased,reducing
R108 T96 T95 ThemeOf MIR122 precursors,levels
R109 T95 T97 ThemeOf levels,reduced
R110 T96 T94 ThemeOf MIR122 precursors,increased
R111 T98 T97 ThemeOf synthesis,reduced
R112 T100 T97 CauseOf reducing,reduced
R113 T99 T98 ThemeOf triglycerides,synthesis
R114 T98 T100 ThemeOf synthesis,reducing
R115 T99 T97 ThemeOf triglycerides,reduced
R116 T100 T99 CauseOf reducing,triglycerides
R117 T101 T100 ThemeOf expression,reducing
R118 T102 T100 ThemeOf biosynthesis enzymes,reducing
R119 T102 T101 ThemeOf biosynthesis enzymes,expression
R120 T104 T108 CauseOf RS-2982,reduced
R121 T104 T110 CauseOf RS-2982,increased
R122 T107 T106 ThemeOf lipotoxicity,reduced
R123 T107 T110 ThemeOf lipotoxicity,increased
R124 T109 T106 ThemeOf liver fibrosis,reduced
R125 T109 T108 ThemeOf liver fibrosis,reduced
R126 T109 T112 ThemeOf liver fibrosis,reduced
R127 T111 T110 ThemeOf resistance,increased
R128 T111 T106 ThemeOf resistance,reduced
R129 T111 T108 ThemeOf resistance,reduced
R130 T113 T112 ThemeOf body weight,reduced
R131 T116 T115 ThemeOf levels,increased
R132 T117 T116 ThemeOf MIR122,levels
R133 T116 T118 ThemeOf levels,levels
R134 T117 T115 ThemeOf MIR122,increased
R135 T117 T118 ThemeOf MIR122,levels
R136 T118 T115 ThemeOf levels,increased
R137 T121 T120 ThemeOf expression,increased
R138 T121 T123 ThemeOf expression,associated
R139 T121 T124 ThemeOf expression,with
R140 T122 T121 ThemeOf MIR122,expression
R141 T123 T124 ThemeOf associated,with
R142 T125 T124 ThemeOf increased,with
R156 T133 T135 ThemeOf RS-2982,agonist
R157 T135 T137 CauseOf agonist,increases
R158 T136 T131 ThemeOf RORA,identified
R159 T136 T135 ThemeOf RORA,agonist
R160 T138 T137 ThemeOf expression,increases
R161 T139 T138 ThemeOf MIR122,expression
R162 T139 T137 ThemeOf MIR122,increases
R163 T142 T143 CauseOf RS-2982,reduced
R164 T144 T143 ThemeOf hepatic lipotoxicity,reduced
R165 T145 T143 ThemeOf liver fibrosis,reduced
R166 T146 T143 ThemeOf body weight,reduced
R167 T148 T151 CauseOf Agonists,treatment
R168 T152 T148 ThemeOf NASH,Agonists
R169 T149 T148 ThemeOf RORA,Agonists
R170 T149 T150 ThemeOf RORA,developed
R171 T149 T151 ThemeOf RORA,treatment
R172 T151 T150 ThemeOf treatment,developed
R173 T152 T150 ThemeOf NASH,developed
R174 T152 T151 ThemeOf NASH,treatment